{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:36:54Z","timestamp":1780616214267,"version":"3.54.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The systemic immune-inflammation index (SII) has been considered a novel prognostic biomarker in several types of lymphoma. Our aims were to determine the best statistical relationship between pretreatment SII and survival and to combination of SII and the Memorial Sloan Kettering Cancer Center model (MSKCC) to derive the best prognostic mode in primary central nervous system lymphoma (PCNSL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pretreatment SII and clinical data in 174 newly diagnosed PCNSL patients were included from two retrospective discovery cohorts (n = 128) and one prospective validation cohort (n = 46). A generalized additive model, Kaplan-Meier curve, and Cox analysis were performed. The high risk versus low risk of SII-MSKCC for the PCNSL cutoff point (0\u20131 vs. 2\u20134) was determined by the minimum P-value approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The SII showed a U-shaped relationship with the risk of overall survival (OS; P = 0.006). The patients with low SII or high SII had poorer OS and progression-free survival (PFS) than those with median SII. For PFS and OS, SII-MSKCC was a better predictor than MSKCC alone. The area under the receiver operating characteristic curve of the SII-MSKCC score was 0.84 for OS and 0.78 for PFS in the discovery cohorts. The predictive value of the SII-MSKCC score (OS, 0.88; PFS, 0.95) was verified through the validation cohort. Multivariable Cox analysis and Kaplan-Meier curve showed excellent performance for SII-MSKCC, with significant separation of two groups and better performance than MSKCC alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We propose a new prognostic model using SII, age, and Karnofsky score that outperforms MSKCC alone and enables individualized estimates of patient outcome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1039862","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T04:38:50Z","timestamp":1667968730000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Shengjie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuguang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10121076","article-title":"Primary central nervous system lymphomas: A diagnostic overview of key histomorphologic, immunophenotypic, and genetic features","volume":"10","author":"Lauw","year":"2020","journal-title":"Diagn (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: The memorial Sloan-Kettering cancer center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0625","article-title":"Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI","volume":"18","author":"Wieduwilt","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.076075","article-title":"Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation","volume":"98","author":"Schorb","year":"2013","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3661","article-title":"Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab","volume":"25","author":"De Giorgi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-021-00752-6","article-title":"Systemic inflammation markers and cancer incidence in the UK biobank","volume":"36","author":"N\u00f8st","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0442","article-title":"Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma","volume":"20","author":"Hu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.05.008","article-title":"Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor","volume":"24","author":"Schumacher","year":"2013","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376426","article-title":"Recruitment of monocytes\/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice","volume":"119","author":"Gil-Bernab\u00e9","year":"2012","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.332","article-title":"Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer","volume":"109","author":"Stotz","year":"2013","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67484","article-title":"Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis","volume":"123","author":"Cools-Lartigue","year":"2013","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.639644","article-title":"Prognostic role of blood markers in primary central nervous system lymphoma patients treated with high-dose methotrexate-based therapy","volume":"11","author":"Luo","year":"2021","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618694","article-title":"Complete blood count score model predicts inferior prognosis in primary central nervous system lymphoma","volume":"11","author":"Feng","year":"2021","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.655259","article-title":"Prognostic significance of systemic immune-inflammation index in patients with diffuse Large b-cell lymphoma","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i32.9825","article-title":"Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large b-cell lymphoma patients","volume":"9","author":"Wu","year":"2021","journal-title":"World J Clin cases"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-2067","article-title":"Comparison and exploration of the prognostic value of the advanced lung cancer inflammation index, prognostic nutritional index, and systemic immune-inflammation index in newly diagnosed diffuse large b-cell lymphoma","volume":"10","author":"Liu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s13167-022-00290-5","article-title":"Prognostic significance of pretreatment red blood cell distribution width in primary diffuse large b-cell lymphoma of the central nervous system for 3P medical approaches in multiple cohorts","volume":"13","author":"Li","year":"2022","journal-title":"EPMA J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large b-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European association for neuro-oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S322467","article-title":"Improvement of outcomes of an escalated high-dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study","volume":"13","author":"Li","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/096228029500400302","article-title":"Generalized additive models for medical research","volume":"4","author":"Hastie","year":"1995","journal-title":"Stat Methods Med Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05550-6","article-title":"The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)","volume":"49","author":"Bauckneht","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-032221-115501","article-title":"Innate immunity and cancer pathophysiology","volume":"17","author":"Maiorino","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.701","article-title":"Validation of c-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients","volume":"110","author":"Szkandera","year":"2014","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: a key player in cancer development","volume":"13","author":"Lian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.08.003","article-title":"Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter","volume":"60","author":"Ferrara","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41571-021-00508-x","article-title":"Beneficial autoimmunity improves cancer prognosis","volume":"18","author":"Zitvogel","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large b-cell lymphoma: a comparison of IPI, r-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ b-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2005.05.005","article-title":"Prognostic factors in primary central nervous system lymphomas","volume":"19","author":"Ferreri","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"B34","article-title":"Expression and correlation of IL-2, IL-10 and TNF-\u03b1 in patients with multiple myeloma-infected herpes zoster treated by bortezomib-containing regimen","volume":"13","author":"Liu","year":"2021","journal-title":"Am J Transl Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1039862\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T04:38:52Z","timestamp":1667968732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1039862\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2022.1039862"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1039862","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"article-number":"1039862"}}